News
02-28-2014, 05:40 AM
Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.
More... (http://www.news-medical.net/news/20140228/ACCRU-opens-phase-III-clinical-trial-of-eribulin-compared-to-paclitaxel-for-metastatic-breast-cancer.aspx)
More... (http://www.news-medical.net/news/20140228/ACCRU-opens-phase-III-clinical-trial-of-eribulin-compared-to-paclitaxel-for-metastatic-breast-cancer.aspx)